JP2012525432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525432A5 JP2012525432A5 JP2012508753A JP2012508753A JP2012525432A5 JP 2012525432 A5 JP2012525432 A5 JP 2012525432A5 JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012525432 A5 JP2012525432 A5 JP 2012525432A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- antibody
- heregulin
- binds
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17367009P | 2009-04-29 | 2009-04-29 | |
| US61/173,670 | 2009-04-29 | ||
| PCT/US2010/033058 WO2010127181A1 (en) | 2009-04-29 | 2010-04-29 | Improved antibodies immunoreactive with heregulin-coupled her3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525432A JP2012525432A (ja) | 2012-10-22 |
| JP2012525432A5 true JP2012525432A5 (enExample) | 2013-05-30 |
Family
ID=43032570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508753A Pending JP2012525432A (ja) | 2009-04-29 | 2010-04-29 | ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8362215B2 (enExample) |
| EP (1) | EP2425009A4 (enExample) |
| JP (1) | JP2012525432A (enExample) |
| AU (1) | AU2010242914B2 (enExample) |
| CA (1) | CA2759792A1 (enExample) |
| IL (1) | IL216014A0 (enExample) |
| WO (1) | WO2010127181A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| KR101764453B1 (ko) | 2010-04-09 | 2017-08-02 | 아베오 파마슈티컬즈, 인크. | 항-erbb3 항체 |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| WO2012059857A2 (en) | 2010-11-01 | 2012-05-10 | Symphogen A/S | Pan-her antibody composition |
| US20140134170A1 (en) | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| EP2815765A1 (en) | 2011-03-15 | 2014-12-24 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to ERBB pathway inhibitors |
| MX336197B (es) | 2011-04-19 | 2016-01-11 | Merrimack Pharmaceuticals Inc | Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. |
| US9127065B2 (en) | 2011-05-19 | 2015-09-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-human HER3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| WO2013048883A2 (en) | 2011-09-30 | 2013-04-04 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| EP2764364B1 (en) | 2011-10-06 | 2021-08-18 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
| CN108424456B (zh) * | 2011-11-23 | 2022-04-26 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
| EP2788382A2 (en) * | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| CN108341873B (zh) * | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
| EP2788381A2 (en) * | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
| CN104755500B (zh) | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹的HER3抗原结合蛋白 |
| CN104755499B (zh) | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白 |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2014123227A1 (ja) | 2013-02-08 | 2014-08-14 | 株式会社医学生物学研究所 | ヒトｎｒｇ１タンパク質に対する抗体 |
| EP2821071A1 (en) | 2013-07-04 | 2015-01-07 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for breast cancer treatment |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| KR20160144465A (ko) | 2014-05-14 | 2016-12-16 | 에프. 호프만-라 로슈 아게 | Her3의 베타-헤어핀에 결합하는 항-her3 항체 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| ATE290595T1 (de) * | 1996-07-12 | 2005-03-15 | Genentech Inc | Gamma-heregulin |
| US20090087878A9 (en) | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| WO2003011897A1 (en) * | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| EP1519956B1 (en) * | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| WO2005040339A2 (en) * | 2003-07-18 | 2005-05-06 | The Regents Of The University Of California | Aptamers to human epidermal growth factor receptor-3 |
| US7413868B2 (en) | 2003-11-05 | 2008-08-19 | Trellis Bioscience, Inc. | Use of particulate labels in bioanalyte detection methods |
| ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
-
2010
- 2010-04-29 JP JP2012508753A patent/JP2012525432A/ja active Pending
- 2010-04-29 EP EP10770384A patent/EP2425009A4/en not_active Ceased
- 2010-04-29 WO PCT/US2010/033058 patent/WO2010127181A1/en not_active Ceased
- 2010-04-29 AU AU2010242914A patent/AU2010242914B2/en not_active Ceased
- 2010-04-29 US US12/770,674 patent/US8362215B2/en not_active Expired - Fee Related
- 2010-04-29 CA CA2759792A patent/CA2759792A1/en not_active Abandoned
-
2011
- 2011-10-27 IL IL216014A patent/IL216014A0/en unknown
-
2013
- 2013-01-17 US US13/744,299 patent/US8828388B2/en not_active Expired - Fee Related
-
2014
- 2014-09-02 US US14/475,348 patent/US9321839B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7334177B2 (ja) | 抗ｃｄ７３抗体及びその使用 | |
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| JP2012523848A5 (enExample) | ||
| JP2008529489A5 (enExample) | ||
| TW200639181A (en) | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
| WO2008017963A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
| JP2020534830A5 (enExample) | ||
| CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
| JP2008538289A5 (enExample) | ||
| JP2008508903A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| PH12012502376A1 (en) | Modified antigen binding molecules with altered cell signaling activity | |
| JP2012515226A5 (enExample) | ||
| JP2016500655A5 (enExample) | ||
| JP2008520186A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| IL212056A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| JP2013527761A5 (enExample) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| MX337587B (es) | Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas. | |
| JP2017526339A5 (enExample) | ||
| JP2009545325A5 (enExample) | ||
| JP2012100677A5 (enExample) | ||
| JP2005225884A5 (enExample) |